US-based lung disease therapy developer Airway Therapeutics completed a $6.3m bridge round on Monday that included healthcare provider Cincinnati Children’s Hospital Medical Center.
The round also featured public-private partnership CincyTech, angel investor group Queen City Angels and undisclosed new investors.
Airway is working on a protein replacement treatment for acute and chronic lung disease sufferers starting with infants. It has secured orphan designation status for its lead product, AT-100, for bronchopulmonary dysplasia (BPD) in the US and Europe.
The company…
